Further support for this comes from the fact that mutations in 12 of the DM genes (FARP2, ACTA2, AcOXL, BCL2, BMF, CLPTM1L, CPEB1, CSRNP1, IPCEF1, LPP, ODF1, SERPINB6, mostly overmethylated in cases, some at multiple CpG sites), as well as in 1 DE gene (C11orf21, overexpressed in cases at FDR = 0.086, have been found in GWAS studies to be associated with differential risk of CLL [38–41]. The gene discussed is FARP2; the disease is B-cell chronic lymphocytic leukemia.